Bayer’s Xarelto Holds Promise

wpid-curata__73dc603d0c1f36d6b0149e8d51e5db6a.jpg

http://genericpharmalitigator.com/wp-content/uploads/2013/09/wpid-curata__73dc603d0c1f36d6b0149e8d51e5db6a.jpg

The HealthCare segment of Bayer has several drugs in its portfolio. Xarelto is one of the key revenue drivers at the segment. Xarelto is approved for several indications in the U.S. including stroke prevention in non-valvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE) and reducing the risk of recurrent DVT and PE.

Read the source article at Zacks Investment Research

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>